Assessment of the intrinsic urethral sphincter component function in postprostatectomy urinary incontinence.
Postprostatectomy incontinence remains a disabling condition. Sphincter injury, detrusor instability, and decreased bladder compliance have been previously reported as major factors. The aim of this study was to evaluate the urethral sphincter intrinsic component, which may provide passive continence. A urodynamic evaluation was performed in 20 patients undergoing a radical retropubic prostatectomy in the preoperative period and 3 months after surgery. Patients with disabled urinary incontinence underwent a new urodynamic evaluation 6 months later. The urethral pressure profile was measured just before, then 10, 20, and 30 minutes after the injection of 0.5 mg/kg moxisylyte chlorhydrate, an alpha adrenergic blocker. Three different pressure components were defined in urethral sphincter capacity: baseline, adrenergic, and voluntary. A postoperative intrinsic urethral sphincter pressure component was found in 17 patients and its value was under 6 cm H(2)O in five cases of severe incontinence. No significant difference was observed for these patients on urethral profile components 6 months later. In contrast, in cases of significant intrinsic component value, no incontinence was observed in most patients. Passive continence after radical prostatectomy should be a matter of concern and may also explain paradoxical incontinence, despite high voluntary urethral pressure obtained after reeducation. A follow-up evaluation of the intrinsic sphincter component is suggested, by using an alpha receptor blockage test during urodynamic studies in the management of patients with postprostatectomy incontinence.
Pfister
Christian
C
Department of Urology, Rouen University Hospital, France. christian.pfister@chu.rouen.fr
Cappele
Olivier
O
Dunet
Frederick
F
Bugel
Hubert
H
Grise
Philippe
P
D000317:Adrenergic alpha-Antagonists; D000368:Aged; D006801:Humans; D008297:Male; D008875:Middle Aged; D013948:Moxisylyte; D011312:Pressure; D011446:Prospective Studies; D011468:Prostatectomy / Q000009:adverse effects*; D013565:Sympatholytics; D014521:Urethra / Q000503:physiopathology*; D014549:Urinary Incontinence / Q000209:etiology* / Q000503:physiopathology*; D014563:Urodynamics
D000317:Adrenergic alpha-Antagonists; D013565:Sympatholytics; D013948:Moxisylyte